What is claimed is:

1. A method for treating or preventing cancer in a subject comprising administering a treatment effective amount of a compound belonging to Formulae I, II, III, IV, V, VI, VII, VIII, IX, X, XI, or XII to a subject in need thereof, wherein

Formula I

$$M_2$$
 M_3
 M_4
 N
 R_4
 R_4
 R_4

where M₁, M₂, M₃ and M₄ are each independently selected from the group consisting of carbon, nitrogen, sulfur, oxygen residues and/or an atomic null such that a fused bicyclic ring system providing valence satisfaction and chemical stability is achieved; substitutions at positions M_1 – M₄ on the above atoms may be hydrogen or halogen, such as fluorine, chlorine or bromine, or carbon-linked substituents such as methyl, ethyl, propyl, isopropyl and higher alkyl and aryl analogs, or nitrogen-linked substituents including amine, methylamine, dimethylamine or higher secondary or tertiary alkyl or aryl amines, or oxygen, sulfur- and selenium-linked substituents including hydroxyl, sulfhydryl and selenylhydryl and alkyl and aryl ether analogs thereof, or silicon-, phosphorous- or boron-linked substituents including alkyl or aryl substitutions at these residues, wherein in all cases, linking atoms and linking-atom substituents are as required for valence satisfaction and chemical stability; R₁ may be any atom or substituent other than halogen including hydrogen, methyl, ethyl, benzyl, aryl and substituted analogs thereof; R₂ and R₃ are each independently chosen to be hydrogen, or substituted oxygen-, carbon-, nitrogen- or sulfur-linked substituents such that valence satisfaction and chemical stability are achieved; R2 and R3 may be covalently linked to give a set of monocyclic aza-cycles; R₄ and R₄ may be independently hydrogen, carbon-, oxygen-, nitrogen- or sulfurlinked substituents including methyl, ethyl, isopropyl, higher alkyl and aryl substituents, hydroxyl, sulfhydryl, alkyl and aryl ethers and thioethers, amine, methyl amine, dimethyl

Formula II

amine and higher alkyl and aryl secondary and tertiary amines, wherein in all cases, substitutions are chosen such that valence satisfaction and chemical stability are achieved; R₄ and R₄ may be covalently linked to give a set of cyclic compounds;

where M₁, M₂, M₃ and M₄ are each independently selected from the group consisting of carbon, nitrogen, sulfur, oxygen atoms and/or an atomic null such that a fused bicyclic ring system providing valence satisfaction and chemical stability is achieved; single and multiple substitutions by the substituent(s) Z at positions $M_1 - M_4$ on the above designated carbon, nitrogen and sulfur atoms may be hydrogen or halogen, such as fluorine, chlorine or bromine, or carbon-linked substituents such as methyl, ethyl, propyl, isopropyl and higher alkyl and aryl analogs, or nitrogen-linked substituents including amine, methylamine, dimethylamine or higher secondary or tertiary alkyl or aryl amines, or oxygen-, sulfur- and selenium-linked substituents including hydroxyl, sulfhydryl and selenylhydryl and alkyl and aryl ether analogs thereof, or silicon-, phosphorous- or boron-linked substituents including alkyl or aryl substitutions at these atoms, wherein in all cases, linking atoms and linking-atom substituents are as required for valence satisfaction and chemical stability; R₁ may be any residue other than halogen, including hydrogen, methyl, ethyl, benzyl, aryl and substituted analogs thereof; R2 and R₃ are each independently chosen to be hydrogen, or substituted oxygen-, carbon-, nitrogen- or sulfur-linked substituents such that valence satisfaction and chemical stability are achieved; R2 and R₃ may be covalently linked to give a set of monocyclic aza-cycles; R₄ and R₄ may be independently hydrogen, carbon-, oxygen-, nitrogen- or sulfur-linked substituents including methyl, ethyl, isopropyl, higher alkyl and aryl substituents, hydroxyl, sulfhydryl, alkyl and aryl ethers and thioethers, amine, methyl amine, dimethyl amine and higher alkyl and aryl secondary and tertiary amines, wherein in all cases, substitutions are chosen such that valence

satisfaction and chemical stability are achieved; R₄ and R₄ may be covalently linked to give a set of cyclic compounds;

Formula III

$$Z = \begin{bmatrix} M_{1} & M_{2} & M_{3} & M_{4} & M_{13} & M_{12} & M_{11} & M_{12} & M_{11} & M_{12} & M_{11} & M_{12} & M_{12} & M_{11} & M_{12} & M_{12} & M_{13} & M_{14} & M_{15} &$$

where M₁, M₂, M₃ and M₄ are each independently selected from the group consisting of carbon, nitrogen, sulfur, oxygen residue and/or an atomic null such that a fused bicyclic ring system providing valence satisfaction and chemical stability is achieved; single and multiple substitutions by the substituent(s) Z at positions $M_1 - M_4$ on the above designated carbon, nitrogen and sulfur atoms may be hydrogen or halogen, such as fluorine, chlorine or bromine, or carbon-linked substituents such as methyl, ethyl, propyl, isopropyl and higher alkyl and aryl analogs, or nitrogen-linked substituents including amine, methylamine, dimethylamine or higher secondary or tertiary alkyl or aryl amines, or oxygen-, sulfur- and selenium-linked substituents including hydroxyl, sulfhydryl and selenylhydryl and alkyl and aryl ether analogs thereof, or silicon-, phosphorous- or boron-linked substituents including alkyl or aryl substitutions at these atoms, wherein in all cases, linking residues and linking-atom substituents are as required for valence satisfaction and chemical stability; M5-M14 may be carbon, nitrogen, oxygen or sulfur or any residue other than hydrogen or halogen and, in certain embodiments, may be either a moiety where M₅, M₆, M₇, M₈, M₉, M₁₀, M₁₁, M₁₂, M₁₃ and M₁₄ are each independently selected from the group consisting of carbon, nitrogen, sulfur, oxygen atoms and/or an atomic null such that a monocyclic or bicyclic ring system providing valence satisfaction and chemical stability are achieved; R₂ and R₃ are each independently chosen to be hydrogen, or substituted oxygen-, carbon-, nitrogen- or sulfur-linked substituents such that valence satisfaction and chemical stability are achieved; R₂ and R₃ may be covalently linked to give a set of monocyclic aza-cycles; R4 and R4 may be independently hydrogen, carbon-,

oxygen-, nitrogen- or sulfur-linked substituents including methyl, ethyl, isopropyl, higher alkyl and aryl substituents, hydroxyl, sulfhydryl, alkyl and aryl ethers and thioethers, amine, methyl amine, dimethyl amine and higher alkyl and aryl secondary and tertiary amines, wherein in all cases, substitutions are chosen such that valence satisfaction and chemical stability are achieved; R_4 and $R_{4'}$ may be covalently linked to give a set of cyclic compounds; Formula IV

where M₁, M₂, M₃ and M₄ are each independently selected from the group consisting of carbon, nitrogen, sulfur, oxygen residue and/or an atomic null such that a fused bicyclic ring system providing valence satisfaction and chemical stability is achieved; single and multiple substitutions by the substituent(s) Z at positions $M_1 - M_4$ on the above designated carbon, nitrogen and sulfur atoms may be hydrogen or halogen, such as fluorine, chlorine or bromine, or carbon-linked substituents such as methyl, ethyl, propyl, isopropyl and higher alkyl and aryl analogs, or nitrogen-linked substituents including amine, methylamine, dimethylamine or higher secondary or tertiary alkyl or aryl amines, or oxygen-, sulfur- and selenium-linked substituents including hydroxyl, sulfhydryl and selenylhydryl and alkyl and aryl ether analogs thereof, or silicon-, phosphorous- or boron-linked substituents including alkyl or aryl substitutions at these atoms, wherein in all cases, linking residues and linking-group substituents are as required for valence satisfaction and chemical stability; M5-M14 may be carbon, nitrogen, oxygen or sulfur or any atom other than hydrogen or halogen and, in certain embodiments, may be either a moiety where M₅, M₆, M₇, M₈, M₉, M₁₀, M₁₁, M₁₂, M₁₃ and M₁₄ are each independently selected from the group consisting of carbon, nitrogen, sulfur, oxygen atoms and/or an atomic null such that a monocyclic or bicyclic ring system providing valence satisfaction and chemical stability are achieved; furthermore, single and multiple substitutions

by the substituent(s) Y at positions M₅ - M₁₄ on the above designated carbon, nitrogen and sulfur atoms may be hydrogen or halogen, or substituted oxygen-, carbon-, nitrogen- or sulfurlinked substituents including methyl, ethyl, isopropyl, higher alkyl and aryl substituents, hydroxyl, sulfhydryl, alkyl and aryl ethers and thioethers, amine, methyl amine, dimethyl amine and higher alkyl and aryl secondary and tertiary amines such that valence satisfaction and chemical stability are achieved; R₂ and R₃ are each independently chosen to be hydrogen, oxygen-, carbon-, nitrogen- or sulfur-linked substituents including methyl, ethyl, isopropyl, higher alkyl and aryl substituents, hydroxyl, sulfhydryl, alkyl and aryl ethers and thioethers, amine, methyl amine, dimethyl amine and higher alkyl and aryl secondary and tertiary amines for valence satisfaction; R₂ and R₃ may be covalently linked to give a set of monocyclic azacycles; R₄ and R₄ may be independently hydrogen, carbon-, oxygen-, nitrogen- or sulfur-linked substituents including methyl, ethyl, isopropyl, higher alkyl and aryl substituents, hydroxyl, sulfhydryl, alkyl and aryl ethers and thioethers, amine, methyl amine, dimethyl amine and higher alkyl and aryl secondary and tertiary amines, wherein in all cases, substitutions are chosen such that valence satisfaction and chemical stability are achieved; R4 and R4' may be covalently linked to give a set of cyclic compounds;

Formula V

$$Z = \begin{pmatrix} M_6 & M_7 & M_9 \\ M_1 & M_{13} & M_{11} \end{pmatrix}$$

$$M_1 & M_{13} & M_{11} & M_{10} \\ M_2 & M_3 & M_4 & M_4 & M_{13} & M_{11} \end{pmatrix}$$

where M_1 , M_2 , M_3 and M_4 are each independently selected from the group consisting of carbon, nitrogen, sulfur, oxygen residue and/or an atomic null such that a fused bicyclic ring system providing valence satisfaction and chemical stability is achieved; single and multiple substitutions by the substituent(s) Z at positions $M_1 - M_4$ on the above designated carbon, nitrogen and sulfur atoms may be hydrogen or halogen, such as fluorine, chlorine or bromine, or carbon-linked substituents such as methyl, ethyl, propyl, isopropyl and higher alkyl and aryl

analogs, or nitrogen-linked substituents including amine, methylamine, dimethylamine or higher secondary or tertiary alkyl or aryl amines, or oxygen-, sulfur- and selenium-linked substituents including hydroxyl, sulfhydryl and selenylhydryl and alkyl and aryl ether analogs thereof, or silicon-, phosphorous- or boron-linked substituents including alkyl or aryl substitutions at these atoms, wherein in all cases, linking atoms and linking-atom substituents are as required for valence satisfaction and chemical stability; in certain embodiments, -A- may be any disubstituted residue, such as oxygen or sulfur, or a trisubstituted residue, such as nitrogen, or a tetrasubstituted residue, such as carbon, or any other residue capable of forming two or more stable bonds; furthermore, M₅, M₆, M₇, M₈, M₉, M₁₀, M₁₁, M₁₂, M₁₃ and M₁₄ are each independently selected from the group consisting of carbon, nitrogen, sulfur, oxygen atoms and/or an atomic null such that a monocyclic or bicyclic ring system providing valence satisfaction and chemical stability are achieved; furthermore, single and multiple substitutions by the substituent(s) Y at positions $M_5 - M_{14}$ on the above designated carbon, nitrogen and sulfur atoms may be hydrogen or halogen, such as fluorine, chlorine or bromine, or substituted oxygen-, carbon-, nitrogen- or sulfur-linked substituents including methyl, ethyl, isopropyl, higher alkyl and aryl substituents, hydroxyl, sulfhydryl, alkyl and aryl ethers and thioethers. amine, methyl amine, dimethyl amine and higher alkyl and aryl secondary and tertiary amines such that valence satisfaction and chemical stability are achieved; R₂ and R₃ are each independently chosen to be hydrogen, oxygen-, carbon-, nitrogen- or sulfur-linked substituents including methyl, ethyl, isopropyl, higher alkyl and aryl substituents, hydroxyl, sulfhydryl, alkyl and aryl ethers and thioethers, amine, methyl amine, dimethyl amine and higher alkyl and aryl secondary and tertiary amines for valence satisfaction; R2 and R3 may be covalently linked to give a set of monocyclic aza-cycles; R₄ and R₄ may be independently hydrogen, carbon-, oxygen-, nitrogen- or sulfur-linked substituents including methyl, ethyl, isopropyl, higher alkyl and aryl substituents, hydroxyl, sulfhydryl, alkyl and aryl ethers and thioethers, amine, methyl amine, dimethyl amine and higher alkyl and aryl secondary and tertiary amines, wherein in all cases, substitutions are chosen such that valence satisfaction and chemical stability are achieved; R₄ and R₄ may be covalently linked to give a set of cyclic compounds: Formula VI

$$M_{1}$$
 M_{1}
 M_{2}
 M_{2}
 M_{2}
 M_{2}
 M_{2}
 M_{2}
 M_{2}
 M_{2}
 M_{2}

where M₁, M₂, M₃ and M₄ are each independently selected from the group consisting of carbon, nitrogen, sulfur, oxygen residue and/or an atomic null such that a fused bicyclic ring system providing valence satisfaction and chemical stability is achieved, single and multiple substitutions by the substituent(s) Z at positions $M_1 - M_4$ on the above designated carbon, nitrogen and sulfur atoms may be hydrogen or halogen, such as fluorine, chlorine or bromine, or carbon-linked substituents such as methyl, ethyl, propyl, isopropyl and higher alkyl and aryl analogs, or nitrogen-linked substituents including amine, methylamine, dimethylamine or higher secondary or tertiary alkyl or aryl amines, or oxygen-, sulfur- and selenium-linked substituents including hydroxyl, sulfhydryl and selenylhydryl and alkyl and aryl ether analogs thereof, or silicon-, phosphorus- or boron-linked substituents including alkyl or aryl substitutions at these residues, wherein in all cases, linking residues and linking-atom substituents are as required for valence satisfaction and chemical stability; in certain embodiments, -A- may be any disubstituted residue, such as oxygen or sulfur, or a trisubstituted residue, such as nitrogen, or a tetrasubstituted residue, such as carbon, or any other atom capable of forming two or more stable bonds; furthermore, M₅, M₆, M₇, M₈, M₉, M_{10} , M_{11} , M_{12} , M_{13} and M_{14} are each independently selected from the group consisting of carbon, nitrogen, sulfur, oxygen atoms and/or an atomic null such that a monocyclic or bicyclic ring system providing valence satisfaction and chemical stability are achieved; single and multiple substitutions by the substituent(s) Y at positions $M_5 - M_{14}$ on the above designated carbon, nitrogen and sulfur atoms may be hydrogen or halogen, such as fluorine, chlorine or

bromine, or substituted oxygen-, carbon-, nitrogen- or sulfur-linked substituents including methyl, ethyl, isopropyl, higher alkyl and aryl substituents, hydroxyl, sulfhydryl, alkyl and aryl ethers and thioethers, amine, methyl amine, dimethyl amine and higher alkyl and aryl secondary and tertiary amines such that valence satisfaction and chemical stability are achieved; R₂ and R₃ are each independently chosen to be hydrogen, oxygen-, carbon-, nitrogenor sulfur-linked substituents including methyl, ethyl, isopropyl, higher alkyl and aryl substituents, hydroxyl, sulfhydryl, alkyl and aryl ethers and thioethers, amine, methyl amine, dimethyl amine and higher alkyl and aryl secondary and tertiary amines for valence satisfaction; R₂ and R₃ may be covalently linked to give a set of monocyclic aza-cycles; wherein in certain embodiments, R₂ is a moiety containing two residues other than hydrogen and no more than eight residues other than hydrogen; M₁₅-M₂₄ may be independently carbon, nitrogen, oxygen or sulfur or any residue other than hydrogen or halogen and, in certain embodiments, may be either a moiety where M_{15} , M_{16} , M_{17} , M_{18} , M_{19} , M_{20} , M_{21} , M_{22} , M_{23} and M₂₄ are each independently selected from the group consisting of carbon, nitrogen, sulfur, oxygen residue and/or an atomic null such that a monocyclic or bicyclic ring system providing valence satisfaction and chemical stability are achieved; R₄ and R₄ may be independently hydrogen, carbon, oxygen, nitrogen or sulfur with substitutions as needed for valence satisfaction; R₄ and R₄ may be covalently linked to give a set of cyclic compounds; Formula VII

$$Z = \begin{bmatrix} M_{1} & M_{1}$$

where M₁, M₂, M₃ and M₄ are each independently selected from the group consisting of carbon, nitrogen, sulfur, oxygen atoms and/or an atomic null such that a fused bicyclic ring system

providing valence satisfaction and chemical stability is achieved; single and multiple substitutions by the substituent(s) Z at positions $M_1 - M_4$ on the above designated carbon, nitrogen and sulfur residues may be hydrogen or halogen, such as fluorine, chlorine or bromine, or carbon-linked substituents such as methyl, ethyl, propyl, isopropyl and higher alkyl and aryl analogs, or nitrogen-linked substituents including amine, methylamine, dimethylamine or higher secondary or tertiary alkyl or aryl amines, or oxygen-, sulfur- and selenium-linked substituents including hydroxyl, sulfhydryl and selenylhydryl and alkyl and aryl ether analogs thereof, or silicon-, phosphorus- or boron-linked substituents including alkyl or aryl substitutions at these atoms, wherein in all cases, linking residues and linking-atom substituents are as required for valence satisfaction and chemical stability, wherein in certain embodiments, -A- may be any disubstituted residue, such as oxygen or sulfur, or a trisubstituted residue, such as nitrogen, or a tetrasubstituted residue, such as carbon, or any other residuecapable of forming two or more stable bonds; furthermore, M₅, M₆, M₇, M₈, M₉, M₁₀, M₁₁, M₁₂, M₁₃ and M₁₄ are each independently selected from the group consisting of carbon, nitrogen, sulfur, oxygen residueand/or an atomic null such that a monocyclic or bicyclic ring system providing valence satisfaction and chemical stability are achieved; single and multiple substitutions by the substituent(s) Y at positions $M_5 - M_{14}$ on the above designated carbon, nitrogen and sulfur residue may be hydrogen or halogen, such as fluorine, chlorine or bromine, or substituted oxygen-, carbon-, nitrogen- or sulfur-linked substituents including methyl, ethyl, isopropyl, higher alkyl and aryl substituents, hydroxyl, sulfhydryl, alkyl and aryl ethers and thioethers, amine, methyl amine, dimethyl amine and higher alkyl and aryl secondary and tertiary amines such that valence satisfaction and chemical stability are achieved; R₂ and R₃ are each independently chosen to be hydrogen, oxygen, carbon, nitrogen, or sulfur-linked substituents including methyl, ethyl, isopropyl, higher alkyl and aryl substituents, hydroxyl, sulfhydryl, alkyl and aryl ethers and thioethers, amine, methyl amine, dimethyl amine and higher alkyl and aryl secondary and tertiary amines for valence satisfaction; R₂ and R₃ may be covalently linked to give a set of monocyclic aza-cycles, wherein in certain embodiments, R2 is a moiety containing two residues other than hydrogen and no more than eight residues other than hydrogen; M₁₅-M₂₄ may be independently carbon, nitrogen, oxygen or sulfur or any residue other than hydrogen or halogen and, in certain embodiments, may be either a moiety where M₁₅, M_{16} , M_{17} , M_{18} , M_{19} , M_{20} , M_{21} , M_{22} , M_{23} and M_{24} are each independently selected from the

group consisting of carbon, nitrogen, sulfur, oxygen residues and/or an atomic null such that a monocyclic or bicyclic ring system providing valence satisfaction and chemical stability are achieved; single and multiple substitutions by substituent(s) X at positions $M_{15}-M_{24}$ on the above designated carbon, nitrogen and sulfur atoms may be hydrogen or halogen, such as fluorine, chlorine or bromine, or substituted oxygen-, carbon-, nitrogen- or sulfur-linked substituents including methyl, ethyl, isopropyl, higher alkyl and aryl substituents, hydroxyl, sulfhydryl, alkyl and aryl ethers and thioethers, amine, methyl amine, dimethyl amine and higher alkyl and aryl secondary and tertiary amines such that valence satisfaction and chemical stability are achieved; R₂ and R₃ are each independently chosen to be hydrogen, oxygen-, carbon-, nitrogen- or sulfur-linked substituents including methyl, ethyl, isopropyl, higher alkyl and aryl substituents, hydroxyl, sulfhydryl, alkyl and aryl ethers and thioethers, amine, methyl amine, dimethyl amine and higher alkyl and aryl secondary and tertiary amines for valence satisfaction; R₂ and R₃ may be covalently linked to give a set of monocyclic aza-cycles; R₄ and $R_{4'}$ may be independently hydrogen, carbon-, oxygen-, nitrogen- or sulfur-linked substituents including methyl, ethyl, isopropyl, higher alkyl and aryl substituents, hydroxyl, sulfhydryl, alkyl and aryl ethers and thioethers, amine, methyl amine, dimethyl amine and higher alkyl and aryl secondary and tertiary amines, wherein in all cases, substitutions are chosen such that valence satisfaction and chemical stability are achieved; R₄ and R₄ may be covalently linked to give a set of cyclic compounds;

Formula VIII

Docket No. 13150-70090US

where M₁, M₂, M₃ and M₄ are each independently selected from the group consisting of carbon, nitrogen, sulfur, oxygen residue and/or an atomic null such that a fused bicyclic ring system providing valence satisfaction and chemical stability is achieved; single and multiple substitutions by the substituent(s) Z at positions $M_1 - M_4$ on the above designated carbon, nitrogen and sulfur residues may be hydrogen or halogen, such as fluorine, chlorine or bromine, or carbon-linked substituents such as methyl, ethyl, propyl, isopropyl and higher alkyl and aryl analogs, or nitrogen-linked substituents including amine, methylamine, dimethylamine or higher secondary or tertiary alkyl or aryl amines, or oxygen-, sulfur- and selenium-linked substituents including hydroxyl, sulfhydryl and selenylhydryl and alkyl and aryl ether analogs thereof, or silicon-, phosphorus- or boron-linked substituents including alkyl or aryl substitutions at these atoms, wherein in all cases, linking atoms and linking-atom substituents are as required for valence satisfaction and chemical stability; wherein in certain embodiments, -A- may be any disubstituted residue, such as oxygen or sulfur, or a trisubstituted residue, such as nitrogen, or a tetrasubstituted residue, such as carbon, or any other residue capable of forming two or more stable bonds; furthermore, M₅, M₆, M₇, M₈, M₉, M₁₀, M₁₁, M₁₂, M₁₃ and M₁₄ are each independently selected from the group consisting of a carbon, nitrogen, sulfur, oxygen residue and/or an atomic null such that a monocyclic or bicyclic ring system providing valence satisfaction and chemical stability are achieved; single and multiple substitutions by the substituent(s) Y at positions $M_5 - M_{14}$ on the above designated carbon, nitrogen and sulfur atoms may be hydrogen or halogen, such as fluorine, chlorine or bromine, or substituted oxygen-, carbon-, nitrogen- or sulfur-linked substituents including methyl, ethyl, isopropyl, higher alkyl and aryl substituents, hydroxyl, sulfhydryl, alkyl and aryl ethers and thioethers, amine, methyl amine, dimethyl amine and higher alkyl and aryl secondary and tertiary amines such that valence satisfaction and chemical stability are achieved; R₂ and R₃ are each independently chosen to be hydrogen, oxygen-, carbon-, nitrogen- or sulfur-linked substituents including methyl, ethyl, isopropyl, higher alkyl and aryl substituents, hydroxyl, sulfhydryl, alkyl and aryl ethers and thioethers, amine, methyl amine, dimethyl amine and higher alkyl and aryl secondary and tertiary amines for valence satisfaction; R2 and R3 may be covalently linked to give a set of monocyclic aza-cycles; R2 may be a moiety containing two residues other than hydrogen and no more than eight residues other than hydrogen, wherein in certain embodiments, -B- may be any disubstituted residue, such as oxygen or sulfur, or a trisubstituted

residue, such as nitrogen, or a tetrasubstituted residue, such as carbon, or any other residue capable of forming two or more stable bonds; linker -B- may be chosen as an atomic null through an octa-atomic set of non-hydrogen atoms such that valence satisfaction and chemical stability are achieved; furthermore, M₁₅-M₂₄ may be independently carbon, nitrogen, oxygen or sulfur or any residue other than hydrogen or halogen and, in certain embodiments, may be either a moiety where M_{15} , M_{16} , M_{17} , M_{18} , M_{19} , M_{20} , M_{21} , M_{22} , M_{23} and M_{24} are each independently selected from the group consisting of a carbon, nitrogen, sulfur, oxygen residue and/or an atomic null such that a monocyclic or bicyclic ring system providing valence satisfaction and chemical stability are achieved; single and multiple substitutions by substituent(s) X at positions $M_{15} - M_{24}$ on the above designated carbon, nitrogen and sulfur residue may be hydrogen or halogen, such as fluorine, chlorine or bromine, or substituted oxygen-, carbon-, nitrogen- or sulfur-linked substituents including methyl, ethyl, isopropyl, higher alkyl and aryl substituents, hydroxyl, sulfhydryl, alkyl and aryl ethers and thioethers, amine, methyl amine, dimethyl amine and higher alkyl and aryl secondary and tertiary amines such that valence satisfaction and chemical stability are achieved, wherein in all cases, substitutions are chosen such that valence satisfaction and chemical stability are achieved; R₄ and R₄ may be covalently linked to give a set of cyclic compounds;

Formula IX

where $M_{25} - M_{28}$ are independently selected from the group consisting of carbon, nitrogen, sulfur, oxygen residue and/or an atomic null such that a mono-cyclic system of at least 4 residues and no more than 7 residues displaying valence satisfaction and chemical stability is achieved; substitution(s) (W) at positions $M_{25} - M_{28}$ on the above residues may be hydrogen or halogen, such as fluorine, chlorine or bromine, or carbon-linked substituents such as methyl, ethyl, propyl, isopropyl and higher alkyl and aryl analogs, or nitrogen-linked substituents including amine, methylamine, dimethylamine or higher secondary or tertiary alkyl or aryl amines, or oxygen-, sulfur- and selenium-linked substituents including hydroxyl, sulfhydryl

and selenylhydryl and alkyl and aryl ether analogs thereof, or silicon-, phosphorous- or boron-linked substituents including alkyl or aryl substitutions at these residues, wherein in all cases, linking atoms and linking-atom substituents are as required for valence satisfaction and chemical stability; R_5 may be any carbon-linked moiety including methyl, ethyl, benzyl, aryl and substituted analogs thereof; R_6 is independently chosen to be a carbon- or nitrogen-linked substituent such that valence satisfaction and chemical stability are achieved; R_7 is hydrogen or a carbon-linked substituent such as methyl, ethyl, isopropyl, higher alkyl, benzyl or aryl and substituted analogs thereof;

Formula X

where $M_{29} - M_{32}$ are independently selected from the group consisting of carbon, nitrogen, sulfur, oxygen residue and/or an atomic null such that a tri-cyclic system displaying valence satisfaction and chemical stability is achieved; substitution(s) (V) at positions $M_{29} - M_{32}$ on the above atoms may be hydrogen or halogen, such as fluorine, chlorine or bromine, or carbon-linked substituents such as methyl, ethyl, propyl, isopropyl and higher alkyl and aryl analogs, or nitrogen-linked substituents including amine, methylamine, dimethylamine or higher secondary or tertiary alkyl or aryl amines, or oxygen-, sulfur- and selenium-linked substituents including hydroxyl, sulfhydryl and selenylhydryl and alkyl and aryl ether analogs thereof, or silicon-, phosphorous- or boron-linked substituents including alkyl or aryl substitutions at these atoms, wherein in all cases, linking atoms and linking-atom substituents are as required for valence satisfaction and chemical stability; R_8 may be any carbon- or nitrogen-linked moiety including methyl, ethyl, benzyl, aryl and substituted analogs thereof; R_9 is independently chosen to be a carbon-linked substituent such as methyl, ethyl, isopropyl, higher alkyl, benzyl or aryl and substituted analogs thereof; R_8 and R_9 may be covalently joined to give a cyclic structure;

Formula XI

where $M_{33} - M_{36}$ are selected from the group consisting of carbon or nitrogen, and/or atomic null(s) such that a monocyclic or acyclic system displaying valence satisfaction and chemical stability is achieved; substitution(s) (U) at positions $M_{33} - M_{36}$ on the above residues may be hydrogen or carbon-linked substituents such as methyl, ethyl, propyl, isopropyl and higher alkyl and aryl analogs, or nitrogen-linked substituents including amine, methylamine, dimethylamine or higher secondary or tertiary alkyl or aryl amines, or oxygen-, sulfur- and selenium-linked substituents including hydroxyl, sulfhydryl and selenylhydryl and alkyl and aryl ether analogs thereof, or silicon-, phosphorus- or boron-linked substituents including alkyl or aryl substitutions at these atoms, wherein in all cases, linking atoms and linking-atom substituents are as required for valence satisfaction and chemical stability; R_{10} may be any carbon- or nitrogen-linked moiety including methyl, ethyl, benzyl, aryl and substituted analogs thereof; R_{11} is independently chosen to be a carbon-linked substituent such as methyl, ethyl, ethyl amine, isopropyl, higher alkyl, benzyl or aryl and substituted analogs thereof; Formula XII

where M₃₇ is selected from the group consisting of substituted carbon, M₃₈ is selected from the group consisting of carbon and sulfur and M₃₉ is selected from either oxygen or sulfur and M₄₀ is selected from either substituted carbon or substituted nitrogen to provide a system displaying valence satisfaction and chemical stability; M₃₇ and M₄₀ may be covalently joined to provide a cyclic system; substitution(s) at positions M₃₇ and M₄₀ on the above residues may be hydrogen or carbon-linked substituents such as methyl, ethyl, propyl, isopropyl and higher alkyl and aryl analogs, or nitrogen-linked substituents including amine, methylamine, dimethylamine or higher secondary or tertiary alkyl or aryl amines, or oxygen-, sulfur- and selenium-linked

substituents including hydroxyl, sulfhydryl and selenylhydryl and alkyl and aryl ether analogs thereof, or silicon-, phosphorus- or boron-linked substituents including alkyl or aryl substitutions at these residues, wherein in all cases, linking atoms and linking-atom substituents are as required for valence satisfaction and chemical stability.

- 2. The method according to claim 1, wherein the compound is any one of Compound No.1 through 188 as set forth in Tables 2 to 5.
- 3. The method according to claim 2, wherein the compound belonging to Formulae I, II, III, IV, V, VI, VII, or VIII is Compound No. 1-5, 7, 11, 13-15, 17-24, 26, 28-31, 42-48, 51, 55-106, 173, 174-179, 184, 185, or 186.
- 4. The method according to claim 3, wherein the compound is Compound No. 28, 173, 184, or 185.
- 5. The method according to claim 2, wherein the compound belonging to Formula IX is Compound No. 33, 50, 166-172, 180-183, or 188.
- 6. The method according to claim 5, wherein the compound is Compound No.182 or 188.
- 7. The method according to claim 2, wherein the compound belonging to Formula X is Compound No. 8, 25, 115, 118, 120, 122-128, 130-132, or 134.
- 8. The method according to claim 7, wherein the compound is Compound No. 118 or 125.
- 9. The method according to claim 2, wherein the compound belonging to Formula XI is Compound No. 35, 107-113, or 114.
- 10. The method according to claim 9, wherein the compound is Compound No. 107 or 109.
- 11. The method according to claim 2, wherein the compound belonging to Formula XII is Compound No. 6, 9, 10, 12, 16, 27, 32, 34, 36-41, 49, 52-54, 116, 117, 119, 121, 129, 133, 135-165, or 187.
- 12. The method according to claim 1, comprising
- (i) testing a bodily sample from the subject for aberrant expression of MUC1; and
- (ii) treating the subject in need of the compound with the compound.
- 13. The method according to claim 12, wherein the compound belongs to Formulae I, II, III, IV, V, VI, VII, or VIII.
- 14. The method according to claim 12, wherein the compound belongs to Formulae IX, X, XI, or XII.

- 15. The method according to claim 1, wherein aberrant expression is loss of clustering pattern of MUC1 on apical border of cell and uniform distribution over cell surface and/or over-expression of MUC1.
- 16. The method according to claim 12, wherein aberrant expression is membrane staining that uniformly covers a cell when contacted with an agent or antibody that recognizes nat-PSMGFR, var-PSMGFR or ESPSMGFR peptide.
- 17. A method for treating or preventing MUC1-positive cancers comprising:
- (i) testing a bodily sample for aberrant expression of MUC1; and
- (ii) treating the patient with a compound comprising a MGFR binding region and metal chelator group wherein the metal is zinc, magnesium or nickel.
- 18. The method according to claim 17, wherein the compound inhibits a metal-dependent protein.
- 19. The method according to claim 18, wherein the protein is a kinesin.
- 20. The method according to claim 17, wherein the metal-dependent protein is an enzyme that cleaves MUC1.
- 21. The method according to claim 20, wherein the enzyme is matrix metalloprotease.
- 22. The method according to claim 21, wherein the enzyme is MT1-MMP or MMP-14.
- 23. A method for diagnosing cancer cells, comprising: (i) contacting a population of cells with a MGFR specific ligand bound to a signal generating label; and (ii) assaying for binding of the ligand to MGFR on the surface of the cells, in which the presence of uniform distribution of the signal over the entire cell surface when contacted with the ligand indicates that the cells are cancerous.